What are the standard research dosing schedules and administration protocols for BPC-157 and TB-500?

In scientific literature and clinical observation, BPC-157 and TB-500 use distinct dosing models due to their different half-lives, potency scales, and mechanisms of action. BPC-157 is measured in micrograms (mcg) and administered daily, whereas TB-500 is measured in milligrams (mg) and typically follows a loading and maintenance schedule.

1. BPC-157 Research Dosing Protocols
Because BPC-157 has a shorter half-life (roughly 4 to 6 hours), research protocols require daily or twice-daily dosing to maintain target tissue concentrations.
Standard Injection Protocols
Typical Dose: 250 mcg to 500 mcg per administration.
Daily Frequency: 1–2 times daily. If dosing twice daily (500 mcg–1 mg total per day), injections are spaced 12 hours apart (morning and evening).
Administration Route:
Subcutaneous (SubQ): The most common route, injected into fatty tissue (e.g., abdomen). For joint and tendon injuries, researchers often administer SubQ in close proximity to the injured area for higher local concentration.
Intramuscular (IM): Occasionally used directly into a affected muscle head, though SubQ near the joint yields similar systemic and localized tissue levels.
Cycle Duration: 4 to 8 weeks for acute/chronic soft tissue injury, followed by a 2- to 4-week wash-out period.
Oral Protocol (Gastrointestinal Specific)
Typical Dose: 250 mcg to 500 mcg taken orally twice daily on an empty stomach.
Primary Target: Ulcerative colitis, gastric ulcers, IBS, and gut lining permeability, where direct luminal contact in the GI tract provides maximum efficacy.
2. TB-500 Research Dosing Protocols
TB-500 has a longer half-life and distributes broadly throughout systemic circulation. Rather than daily administration, protocols utilize a two-phase protocol: a Loading Phase to build tissue saturation, followed by a Maintenance Phase.
TB-500 DOSING TIMELINE [Weeks 1 - 4: Loading] [Weeks 5 - 12: Maintenance] 2.0 mg - 2.5 mg 2.0 mg - 2.5 mg Twice per week (4-5 mg/wk) --> Once per week (or once bi-weekly)
Phase 1: Loading Phase (Weeks 1 to 4 or 6)
Goal: Quickly achieve systemic tissue saturation to jumpstart actin regulation and stem cell migration.
Dose: 2.0 mg to 2.5 mg per injection.
Frequency: 2 times per week (e.g., Monday and Thursday).
Total Weekly Loading: 4.0 mg to 5.0 mg per week.
Phase 2: Maintenance Phase (Weeks 5 to 12)
Goal: Maintain therapeutic tissue levels while preventing systemic breakdown during long-term healing.
Dose: 2.0 mg to 2.5 mg per injection.
Frequency: 1 time per week (or once every 2 weeks for conservative protocols).
3. The “Wolverine Stack” Protocol (Combined)
When research protocols combine BPC-157 and TB-500 to address complex joint, tendon, or ligament injuries, the two compounds are administered on complementary schedules:
Parameter
BPC-157 (Local / Structural)
TB-500 (Systemic / Motility)
Dose
250 mcg – 500 mcg per injection
2.0 mg – 2.5 mg per injection
Schedule
1–2 times daily
2x per week (Loading) $\rightarrow$ 1x per week (Maintenance)
Route
SubQ near injury site
SubQ anywhere (Abdomen / Systemic)
Cycle Length
6–8 weeks continuous
8–12 weeks total
Critical Handling Rule: BPC-157 and TB-500 should never be mixed in the same vial prior to storage. While both can be administered during the same session using separate syringes, mixing lyophilisates or concentrated liquids together in a single vial alters peptide stability and risks enzymatic cross-degradation.
4. Reconstitution & Handling Standard Operating Procedure
Both peptides are shipped as lyophilized (freeze-dried) powders and must be reconstituted carefully:
Diluent: Use Bacteriostatic Water (0.9% Benzyl Alcohol) rather than plain sterile water to prevent bacterial growth and keep the solution stable for 28–30 days under refrigeration.
Reconstitution Technique:
Aim the reconstituted water down the glass side wall of the vial rather than shooting it directly onto the lyophilized puck.
Swirl gently until dissolved. Do not shake, as mechanical friction can shear fragile peptide bonds.
Storage:
Unreconstituted (Powder): Stable in a dark freezer at -20°C for months.
Reconstituted (Liquid): Must be stored at 2°C to 8°C (refrigerated) and kept away from direct light.